Closed System Transfer Device Market Regional Analysis and Growth Prospects
Valued at USD 1,098.72 million in 2024, the closed system transfer device market is projected to reach USD 1,270.56 million in 2025 and USD 4,753.71 million by 2034, growing at a CAGR of 14.1% during the forecast period 2025–2034. According to Polaris Market Research, growth is driven by technological advancements, a rising incidence of cancer, expanding healthcare facilities, regulatory compliance, and heightened safety awareness. Closed system transfer devices (CSTDs) transfer drugs between containers without exposing the drug to the environment or healthcare workers to potential contaminants, preventing leakage, spillage, and aerosolization.
Closed System Transfer Device Market Outlook
The Polaris report, published in October 2025, uses 2024 as its base year, with historical data from 2020 to 2023. North America accounted for the largest share of the closed system transfer device market in 2024, supported by high healthcare standards and a large concentration of healthcare facilities. Asia Pacific is expected to grow at the highest CAGR from 2025 to 2034.
Why Safe Handling Drives Adoption
CSTDs are crucial wherever hazardous drug handling is routine, particularly for chemotherapy agents and other toxic medications. Demand is reinforced by cancer prevalence: the World Health Organization reported an estimated 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. At the same time, hospitals, outpatient clinics, and specialty treatment centers continue to expand, increasing the volume of potent drugs handled. In April 2024, the World Bank Group unveiled a plan to help countries provide quality, affordable health services to 1.5 billion people by 2030.
Browse Insights:
https://www.polarismarketresearch.com/industry-analysis/closed-system-drug-transfer-device-market
Type Segmentation: Needleless Systems Take the Lead
By type, the market is segmented into needleless systems and membrane-to-membrane systems. In 2024, the needleless systems segment held a significant share. These devices minimize the risk of needle-stick injuries, which can transmit bloodborne pathogens and other infections, making them attractive to facilities focused on protecting staff. Polaris also notes that needleless systems are often easier to use than traditional needle-based devices, reducing the likelihood of errors and improving efficiency in drug handling.
Greater awareness of these benefits has encouraged adoption across healthcare settings, and key players are investing in research and development to improve the functionality, usability, and safety of needleless systems. ICU Medical, Inc., for example, offers the ChemoLock and ChemoClave needle-free CSTDs, designed to minimize exposure to hazardous drugs and support USP <800> compliance.
Regulatory Momentum and Compliance Standards
Stringent regulations and guidelines set by health authorities further bolster the closed system transfer device market. USP <800> compliance is a recurring design target: in December 2021, B. Braun Medical Inc. introduced the OnGuard 2 Closed System Transfer Device in the United States, helping facilities meet USP <800> standards for handling hazardous drugs. In December 2024, NIOSH updated its List of Hazardous Drugs, adding agents that require closed handling and prompting hospitals to reevaluate device-compatibility matrices.
Key Players in the Closed System Transfer Device Market
Polaris identifies the Closed System Transfer Device major players as B. Braun Medical Inc.; Baxter; BD; Caragen Ltd.; Cormed; Epic Medical; EQUASHIELD; ICU Medical; JMS North America Corporation; Practivet, Inc.; Simplivia; Terumo Corporation; Vygon; West Pharmaceutical Services, Inc.; and YUKON MEDICAL. These companies are focusing on continuous innovation, including needle-free systems, automated transfer solutions, and advanced safety features, while prioritizing regulatory adherence, strategic partnerships, geographic expansion, and product diversification.
Recent developments illustrate the direction of competition. In March 2024, Simplivia launched its SmartCompounders chemo automation solution, enhanced by the Chemfort CSTD. In January 2025, BD showcased new biologic delivery formats and patient self-care solutions at Pharmapack 2025, highlighting its focus on integrating closed-transfer safety features into broader drug-delivery platforms.
Cost as a Market Restraint
Polaris flags the elevated cost of these systems as a significant restraint that may limit adoption in lower-resource healthcare environments. Even so, regulatory pressure, safety awareness, and continued product innovation position the closed system transfer device market for sustained expansion through 2034.
More Trending Latest Reports By Polaris Market Research:
graphite-industry-outlook-what-fueling-market-expansion
when-will-graphene-go-mainstream-market-barriers-and-breakthroughs
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- الألعاب
- Gardening
- Health
- الرئيسية
- Literature
- Music
- Networking
- أخرى
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness